Real World Evidence at Scale
Most RWE studies stall because the data, the operations, and the writing are at three different vendors. We do all of it. 5,000+ partner centres. 60M+ patient lives. 100+ publications. Hypothesis to published paper under one roof.
Study Types
Retrospective, observational, prospective, registries, phase 4, HEOR. We run them all.
Retrospective Studies
60M+ patient lives already in the repository. Generate evidence from existing records -- no prospective enrollment needed. Retrospective studies can deliver results in 8-12 weeks from protocol finalization.
Observational Studies
Treatment patterns, outcomes, safety data -- collected across the multi-site network. Structured capture through electronic CRFs with real-time validation.
Prospective Studies
Forward-looking data collection with protocol-driven enrollment, follow-up schedules, and outcome measurement across the partner centre network.
Registry Programs
Disease-specific and therapy-area registries across 5,000+ sites. Continuous patient enrollment, longitudinal tracking, and periodic outcome reporting.
Phase 4 & Post-Marketing Surveillance
Post-approval safety and efficacy monitoring. Adverse event tracking, comparative effectiveness, and real-world utilization studies for marketed products.
HEOR Studies
Health economics and outcomes research â cost-effectiveness analysis, budget impact modeling, quality-of-life measurement, and value demonstration for payers and regulators.
End-to-End Research Pipeline
Question to publication. Every step under one roof. No handoffs between vendors.
Hypothesis & Design
Data-driven hypothesis generation from existing datasets. Protocol design with study endpoints, sample size, statistical plan, and ethics committee submission.
Site Activation & Enrollment
Centre selection from 5,000+ partner network. Site activation, investigator briefing, and patient enrollment through electronic CRFs with real-time data validation.
Data Collection & Monitoring
Digital data capture with quality control workflows. Site monitoring, query resolution, and data cleaning. Daily activity tracking across all active sites.
Analysis & Biostatistics
Statistical analysis execution â descriptive, inferential, survival, regression, subgroup. Results validated against protocol-defined endpoints.
Medical Writing & Publication
Manuscript preparation, journal selection, submission management, and reviewer correspondence. Published across peer-reviewed journals and the ERWEJournal platform.
Capabilities
Every competency needed for evidence generation. Integrated, not outsourced to six different CROs.
Hypothesis Building
Data-driven hypothesis generation from existing clinical datasets. Epidemiological analysis, unmet need identification, and research question formulation informed by real-world treatment patterns.
Protocol Design
Study protocol development with inclusion/exclusion criteria, endpoint definition, sample size calculation, and statistical analysis plan. Ethics committee submissions and regulatory alignment.
Clinical Operations
Site activation, patient enrollment, data collection via electronic CRFs, site monitoring, query resolution, and quality control. 20+ SOPs aligned with regulatory guidelines.
Compliance & Quality
Data security and confidentiality standards. Independent ethics committee partnerships. Daily activity management for retrospective and prospective studies. Full regulatory alignment.
Biostatistics
Statistical analysis planning and execution. Descriptive and inferential analysis, survival analysis, regression modeling, subgroup analysis, and sensitivity testing.
Medical Writing & Publication
Manuscript preparation, journal selection, and publication management. White papers, medical presentations, caselets, and multimedia content. 100+ publications across peer-reviewed journals.
Research Infrastructure
Engagement at the top, evidence output at the bottom. Clinical operations and analytics in between.
The Data Asset
60M+ patient lives. 10+ years of longitudinal depth. 1B+ clinical parameters. Built over years, not months.
Scale
60M+ patient lives
60M+ unique patient lives across 5,000+ clinical centres. Covers hospitals, diagnostic labs, specialist practices, and primary care. Multi-geography, multi-tier.
Depth
10+ years longitudinal
10+ years of longitudinal clinical data. 1B+ clinical parameters tracked. Demographics, diagnoses, medications, procedures, labs, outcomes, and treatment timelines.
Breadth
25+ therapy areas
25+ therapy areas spanning acute, chronic, super-specialty, and rare diseases. From cardiology and oncology to infectious disease and metabolic conditions.
Therapy Areas
25+ therapeutic domains. The data is already there. The question is what you want to study.
Cardiology
Hypertension, heart failure, coronary artery disease, arrhythmias, and lipid management. Longitudinal outcomes data across acute and chronic cardiac conditions.
Pulmonology
COPD, asthma, interstitial lung disease, and respiratory infections. Treatment patterns, exacerbation rates, and real-world inhaler utilization studies.
Oncology
Solid tumors and hematological malignancies. Treatment sequencing, survival outcomes, biomarker-driven therapy patterns, and supportive care utilization.
Neurology
Epilepsy, stroke, Parkinson's, multiple sclerosis, and neuropathic pain. Disease progression tracking and treatment outcome measurement.
Endocrinology & Metabolic
Diabetes (Type 1 & 2), thyroid disorders, obesity, and metabolic syndrome. HbA1c trajectories, complication rates, and treatment adherence patterns.
Orthopedics & Rheumatology
Arthritis, osteoporosis, joint replacement outcomes, and autoimmune conditions. Surgical outcomes, rehabilitation patterns, and biologic utilization.
Infectious Disease
Antimicrobial stewardship, resistance patterns, treatment outcomes, and real-time epidemiological surveillance. Alert-based infectious disease monitoring.
Rare & Super-Specialty
Rare disease registries, orphan drug utilization, and specialist referral patterns. Small-population evidence generation across 5,000+ partner centres.
ERWEJournal
Proprietary publication platform for real-world clinical evidence.
ERWEJournal
Exclusive Real World Evidence Journal
A digital-first publication platform purpose-built for real-world clinical evidence. Researchers, clinicians, and industry partners publish and access RWE studies spanning retrospective analyses, observational research, registry data, and post-marketing surveillance across 25+ therapy areas.
100+
Publications
25+
Therapy Areas
5000+
Contributing Centres
Evidence Deliverables
We deliver publications, not just data. From manuscripts to conference decks to surveillance platforms.
Peer-Reviewed Publications
Full manuscripts submitted to indexed journals. From data analysis through medical writing to submission management and reviewer correspondence.
ERWEJournal Platform
Proprietary publication platform for real-world evidence. Digital-first, accessible research dissemination for clinicians, researchers, and industry partners.
White Papers & Reports
Data-backed scientific communications for medical affairs teams. Treatment landscape overviews, comparative evidence summaries, and therapy area deep dives.
Medical Presentations
Conference-ready slide decks, poster presentations, and oral presentation support. Data visualization and scientific storytelling for medical conferences.
Digital Scientific Content
Interactive microsites, multimedia content, and digital medical communications. Trackable content distribution for HCP engagement and product commercialization.
Surveillance & Decision Support
Real-time epidemiology platforms, infectious disease surveillance, risk assessment algorithms, and empirical treatment decision support tools.
Compliance & Quality Framework
20+ SOPs. Ethics committee partnerships. Audit-ready documentation. This is not optional in research.
Ethics Committee
Protocol approval
Independent ethics committee partnerships. Protocol review and approval obtained for every study before site activation.
Data Security
De-identified
De-identified data throughout the research lifecycle. Encryption at rest and in transit. Access control and audit logging for every data interaction.
20+ SOPs
Standard procedures
Standard operating procedures covering clinical operations, data management, site monitoring, biostatistics, medical writing, and publication.
Regulatory Alignment
Audit-ready
Procedures aligned with local and international regulatory guidelines. Audit-ready documentation for sponsor and regulatory review.
Who Partners With Us
Pharma, biotech, medical devices, academic centres. If you need real-world evidence, we can generate it.
Pharmaceutical Companies
Post-marketing & med affairs
Post-marketing surveillance, comparative effectiveness, label expansion evidence, and medical affairs content for marketed products.
Medical Device Companies
Performance & registries
Real-world performance data, outcome registries, and post-market clinical follow-up studies for device approvals and reimbursement.
Biotech & Specialty Pharma
Rare disease & orphan drug
Rare disease registries, orphan drug evidence, and small-population studies leveraging the 5,000+ centre network for enrollment.
Academic & Public Health
Epidemiology & research
Epidemiological research, disease burden studies, treatment pattern analysis, and antimicrobial stewardship programs.
Frequently Asked Questions
What types of organizations commission RWE studies through THB?
Pharma companies, device manufacturers, biotech firms, academic medical centres, public health bodies. Studies range from single-product post-marketing surveillance to multi-therapy disease registries. Scale varies -- the process doesn't.
How is patient data handled?
All research uses de-identified data compliant with applicable privacy regulations. Ethics committee approval for every study. 20+ SOPs govern security, confidentiality, and access control. We take this seriously -- one breach would end the business.
What is the typical timeline for a retrospective study?
8-12 weeks from protocol finalization for retrospective studies using the existing repository. The data is already there -- it is the analysis and writing that takes time. Prospective and observational studies depend on enrollment targets and follow-up periods.
What is ERWEJournal?
Our proprietary digital publication platform for real-world evidence. Researchers and clinicians get an accessible, peer-reviewed channel for publishing healthcare research. 100+ publications and growing.
How large is the partner centre network?
5,000+ centres -- hospitals, diagnostic labs, practitioner clinics. Acute care, chronic disease, super-specialty, primary care. This network took years to build. It is what makes multi-site evidence generation possible at this scale.
Can THB support global multi-centre studies?
Yes. The partner network and operational infrastructure support multi-site studies with centralized protocol management, standardized electronic CRFs, and coordinated data collection across geographically distributed centres.
What therapeutic areas are covered?
25+ therapy areas including cardiology, pulmonology, oncology, neurology, endocrinology, infectious disease, orthopedics, rheumatology, nephrology, gastroenterology, and rare diseases. The longitudinal dataset spans acute, chronic, and super-specialty conditions.
OncAccess â Market Access Strategic OS
For pharmaceutical market access teams: model treatment failure economics, design patient assistance programs, and generate global value dossiers.
Generate Real World Evidence at Scale
Hypothesis to publication under one roof. Tell us what you want to study.